NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

NeoGenomics, Inc.NASDAQ: NEO

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 45.6%

Gross margin was 45.6% in Q2 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 42.9%, down 1.0 pp year over year. Over 3 fiscal years it widened by 2.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
45.6%+2.2 pp QoQ
Last fiscal yearDec 2025
38.8%-5.1 pp YoY
LTMJun 2026
42.9%-1.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.0 pp——
1 year-5.1 pp——
3 years+2.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
38.8%
Year-over-year change
-5.1pp

Gross Margin vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 gross margin of 42.9% is the 8th highest of the 10 companies compared; the peer median is 68.2%.
  • Its year-over-year change of -1.0 pp is the 8th highest of 10, against a peer median of +1.0 pp.
  • Over three fiscal years its change of +2.0 pp compares with a peer median of +7.7 pp.
NEO Competitors Peer median
Gross Margin for NEO and competitors
Company Period LTM level YoY 3-year change
BDSXBiodesix, Inc.LTM Mar 202682.1% +3.7 pp+18.1 pp
CSTLCastle Biosciences, Inc.LTM Mar 202677.1% -4.9 pp+2.7 pp
VCYTVeracyte, Inc.LTM Jun 202672.1% +3.8 pp+3.9 pp
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
WGSGeneDx Holdings Corp.LTM Jun 202668.2% +1.0 pp+81.1 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
XGNExagen Inc.LTM Mar 202658.3% -1.0 pp+11.4 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
GRALGRAIL, Inc.LTM Jun 2026-10.8% +45.7 pp+167.1 pp
FRNMFreenome, Inc. Common stock—— ——
Peer median (excluding NEO) 68.2%+1.0 pp+7.7 pp

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.33M509.73M591.64M660.57M727.33M
Cost of Revenue297.27M321.83M347.04M370.47M444.79M
Gross Profit187.06M187.9M244.6M290.1M282.54M
Gross Margin38.6%36.9%41.3%43.9%38.8%
Research & Development21.87M30.33M27.31M31.16M37.08M
Selling, General & Admin283.94M277.91M279.96M310.49M365.34M
Operating Expenses305.81M345.52M352.34M382.21M348.62M
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
EBITDA46.5M(82.33M)(17.61M)(1.51M)(38.69M)
EBITDA Margin9.6%-16.2%-3.0%-0.2%-5.3%
Operating Income(118.75M)(157.62M)(107.74M)(92.11M)(66.08M)
Operating Margin-24.5%-30.9%-18.2%-13.9%-9.1%
Interest Income3.14M6.08M16.9M18.43M9.07M
Interest Expense8.22M7.58M6.91M6.62M3.75M
Other Income / Expenses103.68M(1.72M)10.64M11.43M(44.19M)
Income Before Tax(15.08M)(159.34M)(97.1M)(80.68M)(110.27M)
Pre-Tax Margin-3.1%-31.3%-16.4%-12.2%-15.2%
Income Tax Expense(6.73M)(15.09M)(9.13M)(1.95M)(2.24M)
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (Basic)(0.07)(1.16)(0.70)(0.62)(0.84)
EPS (Diluted)(0.07)(1.16)(0.70)(0.62)(0.84)
Weighted Avg Shares119.96M124.22M125.5M126.66M128.1M
Weighted Avg Shares (Diluted)119.96M124.22M125.5M126.66M128.1M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.